BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, the genomic instability mediated by BCR/ABL1-mediated downregulation of BRCA1 expression in CML and Ph1-ALL is an attractive candidate for targeted therapy with PARPi.